Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
TR2-C52H7 | Cynomolgus | Cynomolgus TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag (MALS verified) |
|
||
TR2-M52H5 | Mouse | Mouse TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag |
|
||
TR2-H82E6 | Human | Biotinylated Human TRAIL R2 / DR5 / TNFRSF10B Protein, Avitag™,His Tag (MALS verified) |
|
||
TR2-H5255 | Human | Human TRAIL R2 / DR5 / TNFRSF10B Protein, Fc Tag |
|
||
TR2-H5229 | Human | Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag |
|
Loaded Human TRAIL R2, Fc Tag (Cat. No. TR2-H5255) on AHC Biosensor, can bind Human TRAIL, His Tag with an affinity constant of 0.146 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Aponermin | Approved | Beijing Shadong Biotech Co Ltd | 沙艾特 | Mainland China | Multiple Myeloma | Wuhan Hiteck Biological Pharma Co Ltd | 2023-11-02 | Multiple Myeloma | Details | |
Aponermin | Approved | Beijing Shadong Biotech Co Ltd | 沙艾特 | Mainland China | Multiple Myeloma | Wuhan Hiteck Biological Pharma Co Ltd | 2023-11-02 | Multiple Myeloma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Dulanermin (Shanghai GeBaiDe) | Phase 3 Clinical | Shanghai Gebaide Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) | Phase 3 Clinical | Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd | Neoplasms | Details | |
Conatumumab | AMG-655 | Phase 2 Clinical | Amgen Inc | Ovarian Neoplasms; Solid tumours; Rectal Neoplasms; Carcinoid Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Sarcoma; Colorectal Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Anti-DR5 CAR-T cell therapy (Shenzhen BinDeBio) | Phase 2 Clinical | Shenzhen Bindebio Ltd | Esophageal Neoplasms; Stomach Neoplasms; Glioma; Carcinoma, Hepatocellular | Details | |
Rilunermin alfa | SCB-313 (TRAIL-Trimer) | Phase 1 Clinical | Hydrothorax; Ascites; Peritoneal Neoplasms; Pleural Effusion, Malignant | Details | |
BI-905711 | BI-905711 | Phase 1 Clinical | Boehringer Ingelheim Gmbh | Pancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms | Details |
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) | CTB-006 | Phase 1 Clinical | Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd | Solid tumours | Details |
Ozekibart | JCT-205; INBRX-109 | Phase 1 Clinical | Adenocarcinoma | Details | |
Oba-01 | Oba-01; Oba01 | Phase 1 Clinical | Yantai Heyuanaidisi Biomedical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
DS-8273 | DS-8273; DS-8273a | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Colorectal Neoplasms; Lymphoma; Melanoma | Details |
Aplitabart | IGM-8444 | Phase 1 Clinical | Igm Biosciences Inc | Solid tumours; Chondrosarcoma; Sarcoma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Dulanermin (Shanghai GeBaiDe) | Phase 3 Clinical | Shanghai Gebaide Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) | Phase 3 Clinical | Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd | Neoplasms | Details | |
Conatumumab | AMG-655 | Phase 2 Clinical | Amgen Inc | Ovarian Neoplasms; Solid tumours; Rectal Neoplasms; Carcinoid Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Sarcoma; Colorectal Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Anti-DR5 CAR-T cell therapy (Shenzhen BinDeBio) | Phase 2 Clinical | Shenzhen Bindebio Ltd | Esophageal Neoplasms; Stomach Neoplasms; Glioma; Carcinoma, Hepatocellular | Details | |
Rilunermin alfa | SCB-313 (TRAIL-Trimer) | Phase 1 Clinical | Hydrothorax; Ascites; Peritoneal Neoplasms; Pleural Effusion, Malignant | Details | |
BI-905711 | BI-905711 | Phase 1 Clinical | Boehringer Ingelheim Gmbh | Pancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms | Details |
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) | CTB-006 | Phase 1 Clinical | Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd | Solid tumours | Details |
Ozekibart | JCT-205; INBRX-109 | Phase 1 Clinical | Adenocarcinoma | Details | |
Oba-01 | Oba-01; Oba01 | Phase 1 Clinical | Yantai Heyuanaidisi Biomedical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
DS-8273 | DS-8273; DS-8273a | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Colorectal Neoplasms; Lymphoma; Melanoma | Details |
Aplitabart | IGM-8444 | Phase 1 Clinical | Igm Biosciences Inc | Solid tumours; Chondrosarcoma; Sarcoma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
This web search service is supported by Google Inc.